David A. Irvine

Glasgow, SCT, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Results from the prospective phase 2 multicentre UK PBSC haplo trial using PTCy pre- or post-stem cells.

Results from the prospective phase 2 multicentre UK PBSC haplo trial using PTCy pre- or post-stem cells.

Journal: British journal of haematology

Published: October 17, 2025

Patient and Caregiver Experiences of CAR T Cell Therapy for Blood Cancer in the UK: A Qualitative Study.

Patient and Caregiver Experiences of CAR T Cell Therapy for Blood Cancer in the UK: A Qualitative Study.

Journal: The patient

Published: July 08, 2025

CD19 chimeric antigen receptor T-cell efficacy and toxicity in adults with Richter's transformation and response to bridging therapy.

CD19 chimeric antigen receptor T-cell efficacy and toxicity in adults with Richter's transformation and response to bridging therapy.

Journal: British journal of haematology

Published: March 01, 2025

TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial.

TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial.

Journal: Nature medicine

Published: January 18, 2024

Critical care utilisation for patients receiving chimeric antigen receptor (CAR) T cell therapy in the UK.

Critical care utilisation for patients receiving chimeric antigen receptor (CAR) T cell therapy in the UK.

Journal: British journal of anaesthesia

Published: December 07, 2023

Improved COVID-19 outcomes in CAR-T patients in the age of vaccination and preemptive pharmacotherapeutics.

Improved COVID-19 outcomes in CAR-T patients in the age of vaccination and preemptive pharmacotherapeutics.

Journal: Leukemia & lymphoma

Published: August 21, 2023

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.

Journal: Blood

Published: October 11, 2022

Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma.

Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma.

Journal: Blood advances

Published: September 26, 2022

Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis.

Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis.

Journal: Leukemia & lymphoma

Published: April 28, 2022

Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.

Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 31, 2021

Implications of CAR-T cell therapy on apheresis services: a Scottish perspective.

Implications of CAR-T cell therapy on apheresis services: a Scottish perspective.

Journal: Journal of clinical apheresis

Published: October 01, 2020

Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.

Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.

Journal: Leukemia

Published: February 02, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026